• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Antibody Drug Conjugates Market Size is Expected to Reach USD 25.38 Billion by 2033, Growing at a CAGR of 8.84%: Straits Research

    1/22/25 11:05:00 AM ET
    $IMGN
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMGN alert in real time by email

    New York, United States, Jan. 22, 2025 (GLOBE NEWSWIRE) -- ADCs, or antibody-drug conjugates, are chemotherapeutic agents explicitly designed to treat cancer cells. Antibody-drug conjugates deliver chemotherapy by fusing a linker to a monoclonal antibody that attaches to a specific target expressed on cancer cells. Inside the cancer cell, a poisonous chemical is released when the ADC attaches to its intended target (a cancer protein or receptor). Linkers, drugs or poisons, monoclonal antibodies, and others are among the most prevalent types of antibody-drug conjugates. A single white blood cell is cloned in order to produce monoclonal antibodies. Each successive antibody produced in this method may be traced to a single parental cell. Adcertis, Kadcyla, and other drugs belong to this category.

    Download Free Sample Report PDF @ https://straitsresearch.com/report/antibody-drug-conjugates-market/request-sample

    Market Dynamics

    Increasing Incidence and Prevalence of Cancer Drives the Global Market

    The rising incidence of cancer is one of the primary drivers of market expansion throughout the forecast period. According to the WHO, cancer is the second most common cause of death worldwide. The International Agency for Research on Cancer projects that there will be 21.9 million new cancer cases in 2025 and 24.6 million in 2030. The number of cancer cases worldwide has increased significantly during the past decade. Additionally, the rising frequency of cancer in emerging nations is driving a significant need for ADCs. According to GLOBOCAN, over 49.2% of all cancer cases worldwide were expected to be reported in Asia in 2020. Therefore, this region continues to be a significant untapped market for ADCs. The general rise in cancer incidence is projected to increase the number of patients undergoing treatment, increasing the need for early diagnosis and therapy.

    Presence of a Strong Product Pipeline Creates Tremendous Opportunities

    Antibody Drug Conjugates (ADCs) are a distinct class of medicines composed of an antibody chemically linked to a cytotoxic substance. The goal of conventional chemotherapy is to eliminate proliferating tumor cells rapidly. Unfortunately, it can also harm healthy growing cells, resulting in negative side effects. On the other hand, ADC is intended to increase therapy efficacy and decrease systemic toxicity. Seagen, Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca, and Daiichi Sankyo are developing and marketing these medications. For instance, in October 2018, Takeda Pharmaceutical and Seagen, Inc. (formerly Seattle Genetics, Inc.) announced that phase 3 clinical trials of Adcetris for treating CD30-expressing peripheral T-cell lymphoma met the primary endpoint. AstraZeneca and Daiichi Sankyo teamed in July 2020 to develop and commercialize novel ADC medicines. This assisted AstraZeneca in expanding its ADC product line.

    Regional Analysis

    North America is the most significant shareholder in the global antibody drug conjugates market and is projected to grow at a CAGR of 21.3% during the forecast period. North America will likely significantly increase during the forecast period due to rising cancer rates and technological developments. Due to technological advancements in countries such as the United States, Canada, and Mexico, the region is witnessing significant growth. In terms of clinical data, North America is a well-developed region. The use of ADCs, which comprise the majority of the existing market, is considered. For instance, in April 2021, Pfizer acquired Amplyx Pharmaceuticals Inc. to produce antibody-drug conjugates and other cancer medications. In addition, the regional market is expanding due to the growing incidence of cancer. The American Cancer Society projects that 1.9 million new cancer cases will be detected in the United States in 2022. The market for antibody-drug conjugates is expected to expand in the United States during the forecast period due to the rising demand for cancer drugs and the increasing number of cancer patients.

    Europe is anticipated to grow at a CAGR of 26.4% over the forecast period. Europe is the second largest market for antibody-drug conjugates worldwide. Antibody-drug conjugates are projected to benefit from Germany's high healthcare expenditures and expanding research institute population. Germany is anticipated to be one of Europe's most lucrative ADC markets. In addition, several German pharmaceutical companies are attempting to enter the ADC market by investing in R&D. For example, Heidelberg Pharma and Tubulis are developing new ADC therapies in the clinical and preclinical stages. Tubulis, a German biotech startup, raised USD 12.3 million in July 2021 to increase research on ADCs, namely to improve on the research that found linker chemistry to be more stable than the technology employed in ADCs such as Seagen's (formerly Seattle Genetics) Adcetris.

    Ask for Customization @ https://straitsresearch.com/report/antibody-drug-conjugates-market/request-sample

    Key Highlights

    • The global antibody drug conjugates market size was valued at USD 11.84 billion in 2024 and is projected to reach from USD 12.89 billion in 2025 to USD 25.38 billion by 2033, growing at a CAGR of 8.84% during the forecast period (2025-2033).
    • Based on technology, the global antibody drug conjugates market is divided into non-cleavable linkers, cleavable linkers, and linerless. The cleavable linkers segment is responsible for the largest market share and is expected to grow at a CAGR of 22.1% over the forecast period.
    • Based on application, the global antibody drug conjugates market is segmented into blood cancer, breast cancer, urothelial cancer, and other cancers. The breast cancer segment owns the highest market share and is projected to grow at a CAGR of 24.7% during the forecast period.
    • North America is the most significant shareholder in the global antibody drug conjugates market and is projected to grow at a CAGR of 21.3% during the forecast period.

    Competitive Players

    1. Seagen Inc. (previously Seattle Genetics Inc.)
    2. Takeda Pharmaceutical Company Limited
    3. AstraZeneca PLC
    4. F. Hoffmann-La Roche Ltd
    5. Pfizer Inc
    6. ImmunoGen Inc
    7. Gilead Sciences Inc
    8. Daiichi Sankyo Company Limited

    Recent Developments

    • March 2023- ImmunoGen, Inc. (NASDAQ:IMGN) awarded Vertex Pharmaceuticals (Vertex) (NYSE:VRTX) the license to conduct research using ImmunoGen's ADC technology to identify novel targeted conditioning agents for use with gene editing.
    • February 2023- AstraZeneca and KYM Biosciences Inc. signed an exclusive license agreement for CMG901, a potential first-in-class antibody-drug conjugate (ADC) targeting Claudin 18.2, a potential therapeutic target in gastric cancer. Under the terms of the license agreement, AstraZeneca will be responsible for the global research, development, manufacturing, and marketing of CMG901.

    Segmentation

    By Technology

    • Cleavable Linker
    • Non-Cleavable Linker
    • Linkerless

    By Applications

    • Blood Cancer
    • Breast Cancer
    • Urothelial Cancer/Bladder Cancer
    • Others

    By Region

    • North America
    • Europe
    • Asia Pacific
    • Middle East And Africa
    • Latin America

    Get Detailed Market Segmentation @ https://straitsresearch.com/report/antibody-drug-conjugates-market/segmentation

    About Straits Research Pvt. Ltd.

    Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.

    Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client's purchase. We overcome our clients' issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.

    Phone: +1 646 905 0080 (U.S.)

    +44 203 695 0070 (U.K.)

    Email: [email protected]

    Follow Us: LinkedIn | Facebook | Instagram | Twitter



    Primary Logo

    Get the next $IMGN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IMGN
    $VRTX

    CompanyDatePrice TargetRatingAnalyst
    Vertex Pharmaceuticals Incorporated
    $VRTX
    5/7/2025Outperform → Peer Perform
    Wolfe Research
    Vertex Pharmaceuticals Incorporated
    $VRTX
    5/6/2025$503.00Outperform → Market Perform
    Leerink Partners
    Vertex Pharmaceuticals Incorporated
    $VRTX
    4/22/2025$535.00Overweight
    Cantor Fitzgerald
    Vertex Pharmaceuticals Incorporated
    $VRTX
    2/12/2025$408.00 → $424.00Sell → Hold
    Canaccord Genuity
    Vertex Pharmaceuticals Incorporated
    $VRTX
    2/11/2025Sell → Hold
    Canaccord Genuity
    Vertex Pharmaceuticals Incorporated
    $VRTX
    1/30/2025$460.00Overweight → Equal Weight
    Wells Fargo
    Vertex Pharmaceuticals Incorporated
    $VRTX
    12/20/2024$600.00 → $535.00Buy
    H.C. Wainwright
    Vertex Pharmaceuticals Incorporated
    $VRTX
    12/19/2024Outperform → Perform
    Oppenheimer
    More analyst ratings

    $IMGN
    $VRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Mckechnie Duncan claimed ownership of 16,130 shares (SEC Form 3)

      3 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

      7/2/25 4:20:57 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, COO Arbuckle Stuart A covered exercise/tax liability with 37,243 shares, decreasing direct ownership by 37% to 63,368 units (SEC Form 4)

      4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

      7/2/25 4:16:51 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Chief Scientific Officer Altshuler David sold $22,084 worth of shares (52 units at $424.69), decreasing direct ownership by 0.22% to 23,281 units (SEC Form 4)

      4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

      5/19/25 5:07:43 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGN
    $VRTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • January 30, 2025 - FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

      For Immediate Release: January 30, 2025 Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals reach the brain.  Journavx is the first dr

      1/30/25 5:46:14 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • March 26, 2024 - FDA Roundup: March 26, 2024

      For Immediate Release: March 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA proposed a ban of electrical stimulation devices intended to reduce or stop self-injurious or aggressive behavior, a step rarely taken by the agency. The agency has determined that these devices present an unreasonable and substantial risk of

      3/26/24 3:38:14 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for ELAHERE issued to IMMUNOGEN INC

      Submission status for IMMUNOGEN INC's drug ELAHERE (SUPPL-5) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 03/22/2024. Application Category: BLA, Application Number: 761310, Application Classification:

      3/22/24 1:48:21 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGN
    $VRTX
    SEC Filings

    See more
    • SEC Form 144 filed by Vertex Pharmaceuticals Incorporated

      144 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

      5/21/25 4:58:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Pharmaceuticals Incorporated filed SEC Form 8-K: Other Events

      8-K - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)

      5/19/25 4:24:32 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Pharmaceuticals Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)

      5/14/25 4:08:09 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGN
    $VRTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

      NetworkNewsWire Editorial Coverage NEW YORK, July 9, 2025 /PRNewswire/ -- Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease worldwide, a toll that is projected to rise in the coming decades (https://ibn.fm/dyQrw). By 2050, the American Cancer Society estimates that annual cancer diagnoses will reach 35 million. While advances in treatment have improved outcomes for some patients, the demand for more effective therapies remains urgent — and the opportunity for innovation and market impact is significant. Calidi Biotherapeutics Inc. (NYSE:CLDI) (Profile) is taking a bold approach to this challenge with a next-generation pl

      7/9/25 8:30:00 AM ET
      $CLDI
      $CRSP
      $CTMX
      $IBRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Vertex to Announce Second Quarter 2025 Financial Results on August 4th

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its second quarter 2025 financial results on Monday, August 4, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Second Quarter 2025 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived we

      7/8/25 4:00:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

      NetworkNewsWire Editorial Coverage NEW YORK, July 7, 2025 /PRNewswire/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide (https://ibn.fm/dyQrw) with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed with cancer every year. Despite significant progress made in treating the disease, there is still a desperate need — and an enormous market potential — for new and more effective cancer drugs. Calidi Biotherapeutics Inc. (NYSE:CLDI) (Profile) is committed to developing a novel approach to treating cancer through the precise delivery of genetic medic

      7/7/25 8:30:00 AM ET
      $CGON
      $CLDI
      $MRK
      $REGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $IMGN
    $VRTX
    Leadership Updates

    Live Leadership Updates

    See more
    • PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

      11/5/24 7:05:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

      11/5/24 7:00:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Vertex Appoints Nancy Thornberry to its Board of Directors

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Nancy Thornberry has been appointed to its Board of Directors as an independent director. Ms. Thornberry has more than 35 years of experience in the pharmaceutical and biotech industries, spanning drug discovery, development and commercialization. She founded and served as Chief Executive Officer of Kallyope until 2021 and remains on its Board of Directors and is Chair of Research & Development. Prior to joining Kallyope, Ms. Thornberry spent more than 30 years at Merck & Co., Inc., most recently as Senior Vice President and Global Franchise Head, Diabetes and Endocrinology, with responsibility for discovery and clinical

      12/5/23 4:01:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGN
    $VRTX
    Financials

    Live finance-specific insights

    See more
    • Vertex to Announce Second Quarter 2025 Financial Results on August 4th

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its second quarter 2025 financial results on Monday, August 4, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Second Quarter 2025 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived we

      7/8/25 4:00:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Reports First Quarter 2025 Financial Results

      — Total revenue of $2.77 billion, a 3% increase compared to Q1 2024; raised the low end of total revenue guidance by $100 million to a new range of $11.85 to $12 billion — — Strong progress with CASGEVY®, ALYFTREK™ and JOURNAVX™ launches — — Povetacicept (pove) IgAN Phase 3 interim analysis (IA) cohort fully enrolled and zimislecel Phase 3 program to complete dosing this quarter, setting up potential filings in 2026; inaxaplin Phase 3 IA cohort on track to complete enrollment in the second half of 2025 — — Four programs already in pivotal development, with pivotal study of pove in primary membranous nephropathy (pMN) to start this year — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

      5/5/25 4:01:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex to Announce First Quarter 2025 Financial Results on May 5th

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals First Quarter 2025 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast

      4/7/25 4:05:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGN
    $VRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

      SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

      4/10/24 12:14:10 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ImmunoGen Inc. (Amendment)

      SC 13G/A - ImmunoGen, Inc. (0000855654) (Subject)

      2/14/24 5:01:40 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ImmunoGen Inc. (Amendment)

      SC 13G/A - ImmunoGen, Inc. (0000855654) (Subject)

      2/14/24 4:26:22 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGN
    $VRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vertex Pharma downgraded by Wolfe Research

      Wolfe Research downgraded Vertex Pharma from Outperform to Peer Perform

      5/7/25 8:37:12 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Pharma downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Vertex Pharma from Outperform to Market Perform and set a new price target of $503.00

      5/6/25 8:04:29 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald resumed coverage on Vertex Pharma with a new price target

      Cantor Fitzgerald resumed coverage of Vertex Pharma with a rating of Overweight and set a new price target of $535.00

      4/22/25 7:35:34 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care